TFF Pharmaceuticals, Inc. (TFFP)
TFFP moved a median of 0.00% 30 minutes after news, and -0.38% by the close. How TFFP actually reacts to news — the realized, point-in-time move the market made, measured across 120 labeled events over the last three years with zero look-ahead.
TFFP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 50% | 101 |
| 30-min | 0.00% | 50% | 111 |
| 60-min | +1.87% | 64% | 115 |
| to close | -0.38% | 48% | 116 |
| Middle 50% of TFFP reactions | -0.73% to +2.65% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 120 |
Half of all TFF Pharmaceuticals, Inc. news events land between -0.73% and +2.65% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when TFFP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TFFP's baseline. Nothing else.
Recent TFFP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| TFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC Deregistration | Press release | PR Newswire | — | — | |
| Form DEFA14A TFF Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | — | — | |
| Form 8-K TFF Pharmaceuticals, For: Jan 28 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form DEF 14A TFF Pharmaceuticals, For: Jan 28 | SEC filing · Form DEF | SEC EDGAR | — | — | |
| Form PRE 14A TFF Pharmaceuticals, For: Dec 11 | SEC filing · Form PRE | SEC EDGAR | -6.32% | -27.94% | |
| Form 8-K TFF Pharmaceuticals, For: Dec 04 | SEC filing · Form 8-K | SEC EDGAR | -1.92% | -23.97% | |
| Form 10-Q TFF Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.99% | -11.96% | |
| Form 8-K TFF Pharmaceuticals, For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | +5.78% | -5.97% | |
| Form NT 10-Q TFF Pharmaceuticals, For: Sep 30 | SEC filing · Form NT | SEC EDGAR | +5.78% | -5.97% | |
| TFF Pharmaceuticals Announces It Will Wind Down Operations | Press release | GlobeNewswire | +5.78% | -5.97% | |
| TFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery | Press release | GlobeNewswire | +0.00% | +1.89% | |
| TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID | Press release | GlobeNewswire | +0.49% | +7.43% | |
| TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization | Press release | GlobeNewswire | -0.93% | -2.01% | |
| TFF Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference | Press release | GlobeNewswire | +0.00% | -4.10% | |
| Form 10-Q TFF Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.98% | -0.98% | |
| Form 8-K TFF Pharmaceuticals, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -0.98% | -0.98% | |
| TFF Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.98% | -0.98% | |
| Form 8-K TFF Pharmaceuticals, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +3.55% | -2.39% | |
| TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection | Press release | GlobeNewswire | +3.55% | -2.39% | |
| Form 8-K TFF Pharmaceuticals, For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | +5.18% | +8.54% | |
| TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities | Press release | GlobeNewswire | -2.98% | -13.93% | |
| TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant Rejection | Press release | GlobeNewswire | +0.00% | +4.97% | |
| Form S-8 TFF Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -1.03% | |
| Form 8-K TFF Pharmaceuticals, For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.78% | |
| TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing | Press release | GlobeNewswire | +0.32% | -5.99% | |
| TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing | Press release | GlobeNewswire | +5.15% | +8.02% | |
| Form 8-K TFF Pharmaceuticals, For: May 17 | SEC filing · Form 8-K | SEC EDGAR | +5.15% | +8.02% | |
| TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection | Press release | GlobeNewswire | — | +4.69% | |
| Form 10-Q TFF Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | +4.69% | |
| Form 8-K TFF Pharmaceuticals, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | — | +4.69% | |
| TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update | Press release | GlobeNewswire | — | +4.69% | |
| Form EFFECT TFF Pharmaceuticals, | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K TFF Pharmaceuticals, For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | -3.00% | -23.97% | |
| TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering | Press release | GlobeNewswire | — | -7.49% | |
| Form EFFECT TFF Pharmaceuticals, | SEC filing · Form EFFECT | SEC EDGAR | -3.88% | -2.85% | |
| Form 8-K TFF Pharmaceuticals, For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | -6.69% | -4.58% | |
| Form S-1/A TFF Pharmaceuticals, | SEC filing · Form S-1 | SEC EDGAR | -6.69% | -4.58% | |
| TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering | Press release | GlobeNewswire | -3.88% | -2.85% | |
| TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting | Press release | GlobeNewswire | — | -14.65% | |
| Form S-1/A TFF Pharmaceuticals, | SEC filing · Form S-1 | SEC EDGAR | +0.00% | -3.26% | |
| Form ARS TFF Pharmaceuticals, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +3.89% | +15.56% | |
| Form DEF 14A TFF Pharmaceuticals, For: Jun 04 | SEC filing · Form DEF | SEC EDGAR | +3.89% | +15.56% | |
| Form DEFA14A TFF Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | +3.89% | +15.56% | |
| Form S-1 TFF Pharmaceuticals, | SEC filing · Form S-1 | SEC EDGAR | +0.00% | -0.32% | |
| TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions | Press release | GlobeNewswire | +0.20% | -11.56% | |
| Form S-1 TFF Pharmaceuticals, | SEC filing · Form S-1 | SEC EDGAR | +4.35% | -3.62% | |
| Form D TFF Pharmaceuticals, | SEC filing · Form D | SEC EDGAR | +2.53% | +5.49% | |
| Form 10-K TFF Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +5.95% | |
| Form 8-K TFF Pharmaceuticals, For: Mar 28 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +5.95% | |
| TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results | Press release | GlobeNewswire | +0.00% | +5.95% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TFFP section they belong to.
Where else TFFP is measured.
TFFP earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is TFF Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled TFFP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 120 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of TFFP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TFFP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.